Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07091279 · ClinicalTrials.gov registry record · Phase 2
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
A Phase 2 study of Autism Spectrum Disorder and Aggression, sponsored by Jeremy Veenstra-vanderweele.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT07091279 is a Phase 2 study of Autism Spectrum Disorder and Aggression that is actively recruiting participants, run by Jeremy Veenstra-vanderweele. The registered enrollment target is 60 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07091279, a Phase 2 study of Autism Spectrum Disorder and Aggression, is actively recruiting participants, sponsored by Jeremy Veenstra-vanderweele.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-alike substance that contains no drug) daily for 12 weeks. After the 12 weeks, all participants will have the opportunity to receive propranolol for an additional 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Propranolol
Study Locations (2)
New York
- New York State Institute for Basic Research (IBR) - Staten Island
- Center for Autism and the Developing Brain - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07091279
The ClinicalTrials.gov registry entry for NCT07091279 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (56% lower). The listed sponsor is Jeremy Veenstra-vanderweele, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07091279 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07091279 about?
NCT07091279 is a clinical study titled "Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism". The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-ali...
What is the current status of trial NCT07091279?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-01-22. Estimated completion is 2028-12.
What conditions does trial NCT07091279 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Aggression, Self-Injury, Challenging Behaviour, Severe Disruptive Behaviour Disorders.
What interventions are being tested in trial NCT07091279?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG).
Who is sponsoring clinical trial NCT07091279?
This trial is sponsored by Jeremy Veenstra-vanderweele, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07091279 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.